Mobble
Health · Drug development · published 2026-08-25 · via Endpoints News

BMS scraps cell therapy manufacturing agreement, Cellares to restructure

Bristol Myers Squibb has terminated its partnership with Cellares after evaluating the manufacturer's Cell Shuttle platform. The decision will lead to a corporate reorganization at Cellares. The move reflects a shift in BMS's external manufacturing strategy for cell therapies.

Read the full article at Endpoints News →
Related stories
FDA grants accelerated approval to Bristol Myers Squibb's iberdomide for relapsed multiple myeloma · Cancer research
This summary is AI-generated and original to Mobble; the linked article is the authoritative source. Original headline: “Bristol Myers ends deal with Cellares, cell therapy manufacturer to reorg.” Browse more stories.